Medical Arts Tower, The Medical City, Pasig City, Philippines.
Curr Opin Ophthalmol. 2013 Jul;24(4):288-90. doi: 10.1097/ICU.0b013e32836229c5.
This review presents current data regarding the use of collagen cross-linking in the management of corneal infections. Infectious keratitis can lead to blindness without proper antimicrobial therapy. The disease can still progress and lead to corneal melt despite early detection and management. The aggressive nature of corneal pathogens and the threat of antibiotic-resistance make it necessary to develop newer ways of managing this rapidly progressive condition.
Collagen cross-linking is a noninvasive ocular surface procedure that is used to effectively strengthen the cornea. This technique presents as a novel treatment option to halt the progression of keratoconus and ectasia. More recently, however, several articles have demonstrated the effectiveness of cross-linking in treating infectious keratitis via direct microbiologic cure and possibly, inhibition of corneal enzymatic degradation by common pathogenic organisms.
Current literature reveals that corneal collagen cross-linking holds promise in treating infectious keratitis. However, larger-scale, randomized, controlled trials comparing cross-linking to standard antibiotic therapy are still warranted to support these findings.
本文综述了目前关于角膜交联在感染性角膜炎治疗中的应用。如果不进行适当的抗菌治疗,感染性角膜炎可能导致失明。即使早期发现和治疗,疾病仍可能进展并导致角膜融解。角膜病原体的侵袭性和抗生素耐药性的威胁使得开发治疗这种快速进展疾病的新方法成为必要。
胶原交联是一种非侵入性的眼表处理方法,用于有效增强角膜。该技术作为一种治疗进展性圆锥角膜和扩张的新治疗选择。然而,最近有几篇文章表明,交联在通过直接微生物学治愈和可能抑制常见致病生物的角膜酶降解方面,对治疗感染性角膜炎有效。
目前的文献表明,角膜胶原交联在治疗感染性角膜炎方面具有潜力。然而,仍需要进行更大规模、随机、对照试验,将交联与标准抗生素治疗进行比较,以支持这些发现。